国际眼科纵览

• 综述 • 上一篇    下一篇

间充质干细胞治疗视网膜色素变性

董力  魏文斌   

  1. 100730 首都医科大学附属北京同仁医院 北京同仁眼科中心 眼内肿瘤诊治研究北京市重点实验室 眼科学与视觉科学北京市重点实验室
  • 收稿日期:2017-08-21 出版日期:2017-12-22 发布日期:2017-12-21
  • 通讯作者: 魏文斌,Email: weiwenbintr@163.com
  • 基金资助:

    北京市医院管理局“登峰”人才培养计划(DFL20150201);科技创新基地培育与发展专项项目(Z151100001615052);国家自然科学基金(81570891)

Research progress of mesenchymal stem cells for the treatment of retinitis pigmentosa

DONG Li, WEI Wen-bin   

  1. Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2017-08-21 Online:2017-12-22 Published:2017-12-21
  • Contact: WEI Wen-bin, Email: weiwenbintr@163.com
  • Supported by:

    Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150201); Science & Technology Project of Beijing Municipal Science & Technology Commission (Z151100001615052); National Natural Science Foundation of China (81570891)

摘要:

视网膜色素变性(retinitis pigmentosa,RP)是全球范围内致盲的重要眼病之一,目前尚无有效手段阻止或逆转病变的发展。间充质干细胞(mesenchymal stem cell,MSC)是成体干细胞的一种,在体内或体外培养诱导下可分化为某一谱系的视网膜细胞,通过细胞替代、神经保护和血管调控等机制起到修复和保护视网膜功能的作用,这为RP的细胞替代疗法提供了可能性。(国际眼科纵览, 2017,  41:   395-399)

Abstract:

Retinitis pigmentosa (RP) is a main cause of blindness throughout the world. So far, there is no effective way to prevent or reverse the development of RP. Mesenchymal stem cell (MSC) is a kind of stem cells, which can differentiate into a specific type of retinal cells when induced in vivo or in vitro. MSCs can repair and protect the retinal function by cell replacement, neuroprotection and vascular regulation, which provide a cellular replacement therapy for RP.(Int Rev Ophthalmol,  2017,  41:   395-399)